Improving Early Recognition of Treatment-Responsive Causes of Rapidly Progressive Dementia: The STAM3 P Score
- PMID: 37782554
- PMCID: PMC10841446
- DOI: 10.1002/ana.26812
Improving Early Recognition of Treatment-Responsive Causes of Rapidly Progressive Dementia: The STAM3 P Score
Abstract
Objective: To improve the timely recognition of patients with treatment-responsive causes of rapidly progressive dementia (RPD).
Methods: A total of 226 adult patients with suspected RPD were enrolled in a prospective observational study and followed for up to 2 years. Diseases associated with RPD were characterized as potentially treatment-responsive or non-responsive, referencing clinical literature. Disease progression was measured using Clinical Dementia Rating® Sum-of-Box scores. Clinical and paraclinical features associated with treatment responsiveness were assessed using multivariable logistic regression. Findings informed the development of a clinical criterion optimized to recognize patients with potentially treatment-responsive causes of RPD early in the diagnostic evaluation.
Results: A total of 155 patients met defined RPD criteria, of whom 86 patients (55.5%) had potentially treatment-responsive causes. The median (range) age-at-symptom onset in patients with RPD was 68.9 years (range 22.0-90.7 years), with a similar number of men and women. Seizures, tumor (disease-associated), magnetic resonance imaging suggestive of autoimmune encephalitis, mania, movement abnormalities, and pleocytosis (≥10 cells/mm3 ) in cerebrospinal fluid at presentation were independently associated with treatment-responsive causes of RPD after controlling for age and sex. Those features at presentation, as well as age-at-symptom onset <50 years (ie, STAM3 P), captured 82 of 86 (95.3%) cases of treatment-responsive RPD. The presence of ≥3 STAM3 P features had a positive predictive value of 100%.
Interpretation: Selected features at presentation reliably identified patients with potentially treatment-responsive causes of RPD. Adaptation of the STAM3 P screening score in clinical practice may minimize diagnostic delays and missed opportunities for treatment in patients with suspected RPD. ANN NEUROL 2024;95:237-248.
© 2023 American Neurological Association.
Conflict of interest statement
Potential conflicts of interest
Nothing to report.
Similar articles
-
Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia.Ann Neurol. 2024 Feb;95(2):299-313. doi: 10.1002/ana.26822. Epub 2023 Nov 10. Ann Neurol. 2024. PMID: 37897306
-
The Etiology of Rapidly Progressive Dementia: A 3-Year Retrospective Study in a Tertiary Hospital in China.J Alzheimers Dis. 2024;100(1):77-85. doi: 10.3233/JAD-240079. J Alzheimers Dis. 2024. PMID: 38848185
-
Neurocognitive features distinguishing primary central nervous system lymphoma from other possible causes of rapidly progressive dementia.Cogn Behav Neurol. 2015 Mar;28(1):1-10. doi: 10.1097/WNN.0000000000000048. Cogn Behav Neurol. 2015. PMID: 25812125 Free PMC article.
-
Autoimmune Encephalitides and Rapidly Progressive Dementias.Semin Neurol. 2019 Apr;39(2):283-292. doi: 10.1055/s-0039-1678583. Epub 2019 Mar 29. Semin Neurol. 2019. PMID: 30925620 Review.
-
Rapidly Progressive Dementia.Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):510-37. doi: 10.1212/CON.0000000000000319. Continuum (Minneap Minn). 2016. PMID: 27042906 Free PMC article. Review.
Cited by
-
Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia.Ann Neurol. 2024 Feb;95(2):299-313. doi: 10.1002/ana.26822. Epub 2023 Nov 10. Ann Neurol. 2024. PMID: 37897306
References
-
- Stamatelos P, Kontokostas K, Liantinioti C, et al. Evolving causes of Rapidly Progressive Dementia: a 5-Year comparative study. Alzheimer Disease & Associated Disorders. 2021;35(4):315–320. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
